Kristoffer C. Valerie, M.S., Ph.D.
Research program member: Developmental Therapeutics
401 College St.
Richmond, VA 23298-0058
Professor, Radiation Oncology, School of Medicine
Professor, Biochemistry and Molecular Biology, School of Medicine
Professor, Microbiology and Immunology, School of Medicine
Professor, Physics, College of Humanities and Sciences
PhD, Royal Institute of Technology, Sweden (1986)
MS, Temple University (1985)
My research interests and expertise are in molecular radiobiology, DNA repair, radiation-induced signaling, glioma biology, animal tumor models, and the development and testing of novel radiosensitizers. My focus is on the roles of ATM, BRCA1, and protein phosphatase 2A in DNA double-strand break (DSB) repair and the DNA damage response (DDR) in glioma cell systems and mouse models. The goal is to use this information for improving cancer treatment. We are currently testing novel ATM kinase inhibitors (ATMi) as potential radiosensitizers for malignant glioma using mouse brain tumor models in close collaboration with AstraZeneca. Our work has led to a human trial with AZD1390, a highly specific and brain-penetrant ATMi that shows great promise. We are also exploring the yin yang relationship between ATM kinase and PP2A in a novel mouse model, and linking the DDR and radiation-induced brain damage with neurodegenerative diseases.
Animal models,Apoptosis,Biomarkers,Cell cycle regulation,Cell signaling,Clinical trials,DNA damage,Drug discovery,Immunotherapy,Mitosis,Radiotherapy,Signal transduction,Targeted therapies,Translational science